Journal:

Article Title:

doi:

Figure Lengend Snippet: Validation of the anti-inflammatory efficacy of candidate drugs in LPS-primed and CSE-stimulated macrophages: ( A ) Schematic diagram of the 96-well plate layout showing the distribution of control, macrophage inflammatory model (MIM; LPS + CSE), and drug treatment groups across three independent replicates. ( B ) Heatmap representation of the raw concentration distribution across the 96-well plate, confirming consistent experimental conditions across all the wells. ( C ) Dose-dependent inhibition of IL-8 secretion by Celecoxib. Compared to the MIM group, Celecoxib treatment significantly reduced IL-8 levels in a concentration-dependent manner ( p = 0.0015 for low dose, p < 0.001 for medium and high doses). ( D ) Dose-dependent inhibition of IL-8 secretion by Lovastatin. Lovastatin administration significantly attenuated IL-8 release across all the tested concentrations ( p < 0.01 for all the doses). ( E ) Dose-dependent inhibition of IL-1β secretion by Celecoxib. Celecoxib robustly suppressed IL-1β levels, with medium and high doses achieving p < 0.001 compared to the MIM group. ( F ) Dose-dependent inhibition of IL-1β secretion by Lovastatin. Lovastatin significantly reduced IL-1β hypersecretion in a dose-dependent manner ( p < 0.01 for low dose, p < 0.001 for medium and high doses). Significance: * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Interleukin-8 (IL-8) was measured using the EasyGo Human IL-8 One-Step ELISA Kit (Cat. No. EK108EG, Multi Sciences, Hangzhou, China), and Interleukin-1β (IL-1β) was evaluated utilizing the Human IL-1β ELISA Kit (Cat. No. EK101B, Multi Sciences).

Techniques: Biomarker Discovery, Control, Concentration Assay, Inhibition